Thank you, Sagar. Good morning to everyone, and thank you for joining us today for our results presentation for the first half of FY 2025. With me, as always, I have Malik Jainudeen, our CFO, who will later take us through the detail of the financials. As an introduction, Monash IVF is a market leader in providing reproductive care in our core assisted reproductive services, diagnostics, genetics, and pathology services, with a large network of IVF and women's ultrasound clinics, service centers, and ever-growing day hospitals across Australia and Southeast Asia. Our experienced and capable team now includes 173 doctors and in excess of 900 scientific, nursing, counseling, and support staff. I would like to take this opportunity to thank every one of our teams for the unrelenting patient-centric mindset that they have. I would now like to touch on the key financials for the half on slide three.
We reported a net profit after tax of AUD 17.3 million. When taking into consideration some non-recurring significant items, post these items, we achieved AUD 15.8 million underlying NPAT for the half, representing a growth of 5.5%, which was in line with guidance as advised at our AGM back in November. We achieved a revenue increase of 11.6% versus the PCP, and our underlying EBITDA increased 10.7% to AUD 35.6 million. Pleasingly, our EBITDA margins were steady at 25%. With a positive outlook, we were able to declare an increased fully franked interim dividend of AUD 0.026 per share. As we move to slide four, to touch on our key operational highlights, all of our businesses, including domestic ARS ultrasound and international, delivered robust growth in revenue and earnings during the first half of FY 2025.
Of critical importance, we have continued to drive better outcomes for our patients, with clinical success rates improving another 1.2% over the last year. In Australia, we had further growth in our ARS market share of 0.6%, with a slight increase in stimulated cycles of 0.5%, which was above the moderate industry decline of 2.1%. Our Western Australia business, being the recent Pivot Fertility and Fertility North acquisitions, performed really well, with this state now comprising 12% of our Australian stimulated cycles. Our ultrasound business continued to consolidate and achieved earnings improvement whilst delivering scanned growth of 0.1% in the first half of FY 2025. This is on the back of solid growth in the previous couple of years. We continue to see the benefits of the strength of our doctor partnerships and being a destination of choice for specialists.
We welcomed another 10 fertility specialists through organic recruitment in FY 2025 to date, including six in the recently entered Perth market. IVF industry demand drivers remain compelling despite some short-term oscillations in some markets and segments over the last 12 months, which followed 12 months of strong industry growth in the calendar year of 2023. Our clinical infrastructure and expansion projects are nearing completion in Australia, gaining strong presence in every mainland capital city, with day hospital expansion allowing greater diversity and strength of revenue as they ramp up. It is worthwhile calling out that our geographical and service diversification brings financial resilience for the group, particularly in light of the short-term industry volatility. Internationally, and specifically in Southeast Asia, our stimulated cycles increased 8.1% versus the PCP, with the international segment underlying EBIT increasing by 74.1%.
Our Kuala Lumpur clinic performed well, and we invested in a new Singapore clinic building capacity and a special patient experience to drive growth in that market. We have a current platform of four clinics in the region now that we have exited an underperforming clinic in Jakarta. We continue to be focused on executing on the pipeline of opportunities in Southeast Asia. On slide five, I wanted to touch on the compelling underlying structural tailwinds in our industry to support volume growth into the future despite some short-term volatility. The Australian IVF market is 21% above pre-COVID levels, reflecting the non-discretionary and resilient demand for IVF services despite prolonged cost of living pressures and a decline in the Australian birth rate. The five-year CAGR for stimulated cycles industry growth is 4%, again demonstrating the resilience of our industry.
The traditional demand drivers, including advanced maternal age, improving pregnancy rates, and favorable government funding, remain strong. However, the cost of living pressures has continued with slow demand for elective egg freezing, which is more discretionary in nature. New demand drivers with new services, growing patient segments, and new channels indicate that over time, the industry growth trajectory could trend towards 3-5%, with new demand drivers supplementing traditional drivers. In summary, whilst the attractive industry fundamentals continue to support growth, growing patient segments and new services are also expected to be growth drivers going forward. It is also worth noting that short-term volatility in industry volumes can occur for various reasons. However, this does not reflect any underlying shift in future demand for IVF services.
We move to slide six to focus on the broader ARS Australian market, where demand for services in Australia continues at historical high levels. The left-hand graph shows half-yearly growth in stimulated cycles. Despite the challenging macro environment, the Australian IVF industry only contracted 1.3% in calendar year 2024. This was off very strong comparables, as the calendar year 2023 Australian industry stimulated cycles were close to all-time highs.
There was significant variability between states in the first half of 2025, with the weakest state-based markets being Victoria, South Australia, and Queensland, and these are our three largest volume states. Although there can be some short-term volatility evident in industry volumes, the industry is sustainably well above pre-pandemic levels, and our diversification of revenues across the Monash ARS in all mainland capital cities, ultrasound, and Southeast Asia limits any impact from localized short-term volatility in particular markets.
The right-hand graph shows the number of Australian cycles per month, noting that a step change in volume in FY 2021, which was post-COVID, and maintaining those volumes into the outlying years up to calendar year 2024. Moving on to slide seven on market share, our stimulated cycle activity performed better than industry as we continued to grow market share in the first half of FY 2025, which has now occurred over a sustained period of five years. Our market share in Australia grew by 0.6% to 21.5% during the first half, as we continued with the momentum gained from the previous years.
We had market share gains in South Australia, Western Australia, and New South Wales whilst we faced into challenging conditions in Victoria, which is our largest operational state. We are happy with our introduction into Western Australia that commenced in June 2023 through the Pivot Fertility and Fertility North acquisitions.
They are both tracking really well and providing us with meaningful market share in what is a new market for us. With 11.1% growth in our frozen embryo transfer cycles, we also accelerated our market share to 21.5% for frozen embryo transfers. As you can see from the graph on the bottom right, we have sustainably built market share by 4.2% over the last five years as we continue to build a strong track record in the Australian market. I would now like to welcome our CFO, Malik Jainudeen, who will take us through the details of our financials.
Thank you, Michael, and good morning, everyone, and thank you for listening. If you're looking at slide nine, it shows an illustration of the build-up of our revenue in the first half. I think the main takeaway around that is it's ultimately a pretty solid result. Many challenges in there, but our strategy over the last six years has continued to diversify our revenue streams, and this half has been a really good illustration of this very fact. Revenue grew by 12% in an environment whereby the industry declined by 2%, as Michael suggested. Importantly, the Fertility North acquisition that occurred in March 2024 contributed to 4% of the revenue growth, and that asset is doing really well. In conjunction with the Pivot business that we bought in 2022 in Perth, Western Australia now contributes approximately 8% of the group's total revenues.
Patient price increases growth for 4% of the growth, following approximately 4-5% price increases across all service lines in the IVF business, which largely offset unit costs across the domestic business. Going into FY 2026, still early to call, but we still believe that and can anticipate that patient price increases will most likely reflect inflation over the next coming months. The international business, as Michael said again, had a reasonable first half with KL growing in stimulated cycles by 12%, Singapore by 8%, and noting that Singapore was disrupted for around six weeks due to the relocation of the new clinic that we've built over November and December.
What is ultimately encouraging is that the revenue in the international business grew by 25%, with some of it driven by average revenue per cycle increasing by close to 30%, particularly in our KL business through both price increases and mix. Ultrasound, again, contributed a further 1% of revenue growth for AUD 1.5 million as our Melbourne ultrasound business continued its strong performance and recovery, which commenced in the second half of last year.
Whilst our Sydney business was somewhat benign or mixed, with the western suburbs doing really well, but the eastern suburbs a little bit slow in terms of its uptake of the demand. Day hospitals becoming a bigger revenue driver in our business contributed to 2% of the revenue growth, and we are doing close to 8,000 episodes in our Melbourne, Sydney, Adelaide, and Gold Coast hospitals, and an average revenue of just over AUD 1,000 per episode.
With Brisbane opening next year, with utilization increasing across most of the hospitals, I think day hospitals will continue to grow and generate further earnings for the business. Genetics revenue, again, important cog in our strategy in terms of growth going into the future. RGS testing, small numbers, but again, grew by circa 80% in terms of activity that generated close to AUD 400,000 or more revenue. If you look at our standard genetics type activity, particularly around PGS testing, which is testing for embryos for chromosomal abnormality, increased revenues by almost AUD 500,000 as well. If you go over to slide 10, just a quick bridge on EBITDA contribution, much of it driven on the back of revenue performance that we spoke about, but we've ultimately increased EBITDA by 11% to AUD 36 million.
This includes the impact from the industry, which essentially had a 5% negative impact on earnings, but we were still able to increase earnings by 11% at the EBITDA line. Domestic IVF business, including acquisitions, generated additional EBITDA of AUD 1.9 million, or 6% of the growth. I think what is important in this result as well is the management of the cost base, particularly in the domestic IVF business, heavy focus on optimization of this cost base, which is occurring in most parts of the business. There is pressure in parts of the business. On the back of that industry decline, we saw a 1% negative impact on our margins, but again, the cost base and growth in other parts of the business has been able to maintain EBITDA margins at 25% compared to last year.
As noted, the Fertility North business tracking well, added AUD 1.4 million of EBITDA, which is exactly where we had it planned, and it's exactly how it's played out. Our international business EBITDA increased by AUD 800,000, driven by both KL and Singapore. In percentage terms, EBITDA grew by 74% in Asia, which is solid, but to be honest, it still has room for more improvement. Ultrasound and day hospitals added AUD 700,000 of EBITDA, providing us with more diversification in our earnings pool. If you go over to slide 11, just a quick summary of the profit and loss. Pretty self-explanatory. Revenue up by 12%, underlying EBITDA up by 11%, and MPAT up by 6%, and noting that margins were maintained.
What we haven't spoken about is just reported EBITDA is actually stronger than the underlying result, and that's on the back of the insurance recovery regarding the class action, which flows straight to the bottom line, which resulted in NPAT actually growing by 35% compared to last year. Reported depreciation amortization was up by AUD 1.7 million. I think that was, again, very much expected due to the new Melbourne and Gold Coast clinics, and we had a full six months of that depreciation come through, as well as non-cash related lease accounting impact of around AUD 500,000 post-tax, again, non-cash on our premises.
Interest up by AUD 800,000, again, expected. You would have seen that our borrowings have gone up by AUD 20 million, purely because of class action settlement payments that occurred in the first half. Slide 12, which has a summary of our cash flow. Again, generation was reasonably solid. Class action payments of AUD 20 million plus the five-odd million of non-cash benefit on the settlement of the insurance proceedings related to the class action impacted our conversion. If you strip it all back, conversion was pretty solid at just under 90%, and I think that underlying conversion by the time we get to the end of the year should be closer to 100%. Tax installments going to be low for the rest of the year. Those class action payments will become deductible in 2025.
A timing difference does not impact profit, but impacts taxable income in 2025. CapEx for the year was AUD 8 million. We spoke about Singapore. That was circa AUD 2.5 million of spend. Patient management system, we haven't spoken about it a lot previously, but it is a big transformational project in our business that we're very excited by, and it will have an impact on our business going forward. CapEx going into the second half should be pretty consistent with the first half.
We still have to finish Brisbane or start Brisbane and finish it towards the start of next year, and you'll see that the borrowings payments were AUD 20 million, all related to the class action. Just over to slide 13, which is the balance sheet. Again, leverage is pretty well contained. Leverage ratio at 1.3 times post-class action settlement payments that occurred in the first half, and we still have another AUD 36 million to pay in the second half, which will be partly funded through insurance proceeds of AUD 17.5 million.
We think the leverage ratio will probably sit around 1.6, 1.5 by the time we get to 30th June. Again, plenty of room available for both organic and non-organic growth expectations going into next year. Just over to slide 14, the first time that you would have seen some trajectory on cost optimisation plans in our business that has been occurring for the last 12 months. It is about optimisation. It is about efficiencies. Our patient management system is a serious key driver of it to eliminate certain blockages in our processes across our business, enhance workflows in our business, and also ultimately, we see it as a real driver for improvement in patient experience and our doctor experience within our business. That is both day-to-day use of the system as well as how we communicate with our patients, both digitally and through other means in the future.
You roll all that up, including standardisation of our workflows, consolidation of some of our clinics, optimisation of some of our smaller clinics that have high fixed costs in those businesses. With a focus on all those levers, we really do believe we can drive 2% margin improvement going into the next couple of years. If you look at that, if you overlay the type of leverage benefit that you can get in this business with volumes going up, we can see margins improving by more than that 2%. Alternatively, if we see some issues in certain parts of our business like we have this year, this will just go a long way to protecting margin with some fluctuations in the short term across some of our jurisdictions as we've seen in this second half or first half. Thanks, Michael. Back to you.
Thank you, Malik. As we move on to slide 16, start to work through some of the details of our Australian ARS operational performance. We'll start with the essential pillar, and we've had a lot of great progress with this over recent years, and that is doctor partnerships. Our success in recruiting new doctors reflects the compelling doctor value proposition and the attraction of joining a group of highly engaged doctors across fertility and ultrasound services. We're continuing to collaborate with existing and prospective clinicians to ensure the doctor value proposition is tailored to their individual needs and promotes long-term career progression. We continue to gather momentum in our doctor recruitment through direct recruitment, having welcomed a total of 73 new clinicians over the last 4.5 years or 4.5 years.
These results can only be achieved when you have a highly engaged doctor group being advocates for Monash IVF as a result of the experience and service quality they and their patients are recipients of. Our focus remains on attracting and onboarding new and experienced fertility specialists in areas where we are underrepresented or where opportunities exist to complement our diverse geographic footprint. The specialists we target must have a suitable cultural fit, outstanding clinical competencies, and industry reputation. Moving to slide 17, a focus on scientific leadership. We have a continued unrelenting focus on investing and building scientific capability to ensure we are giving our patients the best possible outcomes and differentiating our value proposition to patients and doctors.
The chart at the bottom left of this slide represents the continuous improvement in our clinical pregnancy rates across the group, with clinical pregnancies in 2024 increasing by a very significant 7.6% as compared to calendar year 2018, with strong incremental improvement in every single year. That is nearly eight babies per 100 treatments, an achievement we are extremely proud of. It is worthwhile calling out some of the initiatives that will drive further improvements in our science programs and further improvement in our success rates into the future. We will continue to partner innovative organizations to advance new technologies and systems. A few examples of this are a wearable fertility tracker, rolling out of a single-step embryo culture across the group and implementing a new electronic witnessing system.
Partnerships and technologies backed up by an ongoing research focus through our various research bodies will ensure we continue to evolve and improve our success rates and the patient experience, as our history demonstrates. Move on to the clinical infrastructure slide on slide 18, with our investment creating state-of-the-art facilities across fertility, day surgery, and ultrasound services. Our infrastructure transformation is almost complete, with the last new flagship site in Brisbane to be completed later this calendar year. Our flagship facilities will be instrumental in attracting new doctors and patients to Monash IVF, providing a best-in-class experience and the convenience of co-located day surgeries. The returns from the new facilities are in various ramp-up phases as utilization builds. However, they are on track to meet our minimum 20% 10-year return on investment criteria.
As we enter the tail of our significant recent investment in infrastructure, those clinics will support market share gains and provide premium best-in-class experiences for our patients, our clinicians, and our people. As I take you to slide 19, and we'll look at the progress of our recent day surgery investment. In the first half of FY 2025, the day surgery revenue was up AUD 2.8 million, and EBITDA was also up by AUD 300,000 as our utilization improves across all of our sites. With new specialties building and improved uptake from current specialists for our gynae surgical cases, we will continue to improve capacity utilization of our state-of-the-art day surgeries. Furthermore, with some structural changes providing greater coordination and management between the day surgeries, a better, stronger, and more financially successful service will be generated in the future.
As we take a look at slide 20, our substantial strategic marketing investment and campaigns are driving market share gains in both traditional and emerging patient segments. We have launched innovative specialized campaigns. Our egg and sperm donor campaigns are an example of that. More recently, we have launched a campaign around our best-in-class success rates. Moving on to our people, we lead the industry, having recently been approved as a registered training organization. This initiative marks a pivotal step in our commitment to fostering professional development and enhancing the skills of our employees nationwide, whilst also enriching our employer value proposition. Our value proposition ensures we are leading the market in areas of reward and recognition, employee benefits, and a culture that is represented by well above benchmark engagement that will continue to go from strength to strength.
If we take a look at women's imaging performance on slide 21, our women's ultrasound business continued to consolidate on the growth and improvement of business in the previous two years, generating increased earnings for the half. Furthermore, we generated volume growth of 0.9% for the business, with a favorable high-value mix of scans contributing to the earnings growth. Onto genetic carrier screen testing, we are seeing good signs in patient uptake through the Medicare numbers and also our own testing increase in volumes of 80% in the first half of FY 2025. However, this strong demand is yet to flow through to industry IVF cycles.
We believe in the value that carrier screen testing and managing disease risk has in our community, and the lead indicators through testing and the growth in the initial feasibility tests all indicate solid penetration of this test since the introduction of Medicare funding in November 2023. We continue to learn more around the conversion rate from the initial carrier screen test to managing the risk through IVF treatment. We have a view that it takes approximately two years; however, we will learn more in the fullness of time. As we move abroad to our ARS international operation performance, which is on slide 22, we delivered first-half stimulated cycle growth of 8.1% driven by our KL Clinic and Singapore and Bali, which reflected the momentum we carried forward from the second half in FY 2024.
This contributed to an excellent earnings outcome with EBIT increasing 74.1%. The key drivers were the leverage that we benefited from the KL volume growth and the improved performance in Singapore. Singapore delivered really good volume growth at 7.9% despite a disruption caused by moving the new clinic in November 2024. The expanded state-of-the-art Singapore clinic is performing well and expected to attract new doctors and patients. A decision was made to exit an underperforming joint venture in Jakarta, Indonesia. Our minority ownership meant it was challenging to have operational and clinical influence in the joint venture, and there are some key learnings for future investments. Our immediate focus is to optimise our existing clinics and, in particular, drive KL fertility and leverage the recent new clinic investment made in Singapore.
We will also continue to explore new opportunities of scale in the region. Our Vision 2026 strategic roadmap is on slide 26. Many of you will be familiar with our Vision 2026 strategic roadmap as it continues to remain consistent regarding our objectives and aspirations. We have made significant progress in our strategic pillars, and our outcome metrics continue to trend favorably, and this is off the back of compelling improvement over the previous five years. This is quite an achievement and demonstrates the significant progress and momentum we have to ensure we achieve our Vision 2026 objectives. However, there is still more to achieve. As we edge closer to 2026, we will be updating our strategic framework to ensure we continue on our journey to be the most admired reproductive care provider in the world.
As we move on to the all-important outlook statement on slide 25, the Australian ART or assisted reproductive technology sector and Monash IVF will continue to benefit from evolving underlying structural demand drivers, particularly from emerging services such as genetics, donor, and egg freezing. Advanced maternal age and growing patient segments such as the LGBTQIA+ community will continue to drive growth in the ART sector in the medium to long term. Short-term volatility in the domestic ART sector is not uncommon, and the volatility is expected to subside in the near term, supporting and aiding the ongoing resilience and sustainability of the ART sector that has grown by 4% CAGR over the last five years. In phase 22 to phase 24, we made significant investments in future growth, including recent acquisitions, attraction of new fertility specialists, further expansion into Southeast Asia, and day hospitals.
Notwithstanding recent volatility in new patient IVF registrations in certain jurisdictions in Australia, these investments and focus on cost optimisation are supporting stability in financial year 2025 and growth in the long term. Accordingly, our financial year 2025 underlying group NPAP is expected to be between AUD 30 million and AUD 31 million compared to AUD 29.9 million in the prior comparative year. That completes the formal part of our presentation, Sagar, so I'm happy to move to questions now.
Thank you. If you wish to ask a question, please press star one on your telephone and wait for your name to be announced. If you wish to cancel your request, please press star two. If you are on a speakerphone, please pick up the handset to ask your question. Your first question comes from David Stanton from Jefferies. Please go ahead.
Good morning, team, and thanks very much for taking my questions. I've got a couple. With forward registrations down about 180 basis points in first half FY 2025, what does this mean, do you think, for your volume growth that we should expect for FY 2025? Does that mean it'll be flat to down or flat or slightly up?
Hey, Dave. The best way to look at new patient registrations, and obviously they're quoted as the domestic numbers, that is our new patients that will cycle through our business, say, for the next six months. That's 50% of our total cycles domestically. New patients, in theory, will be around 1.8% down is what that implies. The returning patient pipeline was stronger in the first half compared to the prior year or around the mark. I don't think they correlate directly. Yes, an assumption around cycles being flat is a reasonable assumption.
Understood. Thank you. Very clear. I guess you're saying as well, if you look further out, that notwithstanding the issues that we've seen in terms of cost of living pressures, for 2026 plus, I guess, or just for 2026, we should be thinking that 2-3% volume growth for the market at least?
Yeah. Yeah. I expect we'll probably fall back closer to 3-5%, particularly as we start to get some leverage through the volume from the carrier screen testing as well as seeing the market somewhat recover with some relief.
Understood. Final one before I get back in the queue. You've talked to a 2% margin increase by 2027, just because I'm not very clever. Is that EBITDA, EBIT, NPAP?
Good question, Dave. Yes, EBITDA. EBITDA.
EBITDA. That is on a volume base of what we should be thinking about?
I mean, even if there's—what I'm trying to ask is, even if there's flat volumes in that year, God forbid, are we talking a volume—are we still talking that 2% margin increase being possible or not?
Yeah. Yeah. So 2% on a revenue base, for example, of AUD 300 million or close to it for a full 12-month period. Understood.
That's the basis. That's the basis, not the forecast of revenue next year, Dave.
Sure, Understood. Yeah. No, I won't put that in. Thanks a lot.
Thank you. Your next question comes from Craig Wong from RBC. Please go ahead.
Morning. Just wanted to touch on the challenging conditions you've called out in Victoria. Could you just elaborate a bit more on that and whether you've been holding share there?
Yeah. The Victorian market has become really competitive. There's been some breakaway groups, and the pricing positions of some of those are a little bit variable to the premium providers. They've had some reasonably sort of strong initial uptake in numbers. Our market share is just slightly off market in Victoria, not too significantly. We're competing pretty well against some of those players. The overall market is also down, worse than others in the actual state. Yeah, we're putting a lot of effort and focus in moving towards gaining market share. We've got some strategies in place and some demand creation activities that we're implementing now.
Okay. Thanks. That's helpful. Then just on the cost-based reduction, the AUD 1.7 million benefit in this half, just trying to understand what the annualized savings from those initiatives are, how much might sort of be derived in the second half. Yeah.
Craig, most of that was largely executed back half of last year. I would not expect to see a similar type of delta as a difference compared to second half last year, but it will be somewhere in between zero and that number.
Thanks. Then just D&A, that sort of increased a little bit this year. Could you help us with how we should think about the second half D&A number?
It should be consistent with the first half, Craig.
Last question, just on that timeframe between carrier screening and then conversion to IVF treatment, I think you called out, Michael, about two years. Could you just walk us through how you came to that number or how you are thinking about that timeframe?
Yeah. Look, it is still early days, but with carrier screen testing, it is often couples that actually do not have fertility issues. They do have time on their side. There is no sense of urgency. From when they get the test, they understand the implications. They go through the counselling. They come up with a treatment plan to mitigate the risk of the disease and work through the appropriate timing for them. It looks like it is going to be around about two years. We are only a year and three months in from when the test became Medicare funded. We will certainly learn a lot more about that in the next 12 months as well. That is the early indications.
Yep. Okay. Great. Thank you. Thank you.
Your next question comes from Rachael Harwood from Macquarie. Please go ahead.
Yeah. Hi, Michael and Malik. Thanks for taking my question.
Hey, Rachel.
I guess just to follow on, just on that carrier screening test, I guess, how are you seeing people upgrade from that Medicare test to the full panel test? Do you have any update on bringing that maybe onshore to get the funding?
Yeah. We do. First of all, it's still maintaining at 50/50, which is a really good outcome. People have clearly seen the benefit of doing the full panel disease testing, even though it's not Medicare funded. As far as bringing the capability onshore and partnering with a partner, we're expecting that to happen in the next couple of months so that we'll have that capability that will be Medicare funded through a strategic partner in about two months' time, which will make it so much more affordable. We'll see a stronger shift towards the full panel of disease testing.
Yeah. That's great. You touched on the mix a little bit, but just those frozen cycles doing particularly well. Are you noticing much of a shift between new and returning patients?
Hey, Rachel, I think the growth in frozen embryo transfers is obviously returning patients that are coming back into the network. It can be different year to year depending on the quantum and growth in new patients that accessed in cycles in the prior number of years. We have had a good year of sets. If you look back in history, you'll have one good year, you'll have one average year, you'll have one good year. We are in that good year at the moment. It is generally just a reflection of what new patients look like for the last two to three years. It is just catching up. If you look at the market share, for example, our market share for FETs have always been well below stimulated cycles. This is the first time it's caught up in about three years, I reckon.
That's great. Thanks for that.
Thank you. Your next question comes from Martyn Jacobs from Bell Potter Securities. Please go ahead.
Morning, guys. Well done in a tough operating environment. Just a couple from me. The chart, EBITDA or revenue chart says you're down AUD 3.3 million from industry decline. Can you say how much of that was due to Victoria?
A big number in there is Victoria, Martin. I think there's no secret. Yeah. More than half. No secrets in that. The big market is a tough market for us.
Yeah. Moving on to ultrasound. Scan growth only 0.9%, but revenue for scan up 7%. Can you just give me a little more color on the 0.9% volume growth, which looks low compared to prior periods, if I'm not mistaken?
Sorry, Martin. I might have missed the start of it, but Michael, did you?
Yeah. I got it. In regards to the volume growth, yeah, it's a little bit softer. It's probably reflecting a little bit of the birth rate, which is what the high bulk of our scans represent. The reason why the revenue and the earnings still grew really well was because of pricing and also the mix of the higher value scans that were done during that period, which tend to be the more essential scans.
Right. Okay. Do you think that's sustainable, or have you got more price increases coming through beyond the inflation?
Yeah. We review our pricing every 12 months, Martin, across our whole business.
That's generally 1st of July. On the day surgeries—sorry, go on. Yes, it is sustainable. Okay. On the day surgeries, you're getting growth coming through. I think the incremental margin there is just over 10%. What should the natural margin of the day surgery business be? How do you rate how much spare capacity you've got at the moment, given it's relatively new facilities?
Yeah. 15%-20% should be pretty standard. That's assuming you're getting your utilisation in your hospitals, or at least our hospitals, at circa 75%. Break-even is around 65%. The comment about 75% is where our utilisation is, it's slightly below that.
Answering your question about where it can go, there's still a lot more capacity across the majority of our day hospitals, particularly the Gold Coast, which is the multidiscipline, particularly Melbourne, where we're only utilizing one or two theatres. Sydney and Adelaide are single theatre units that are just utilized for IVF procedures primarily, and a little bit of gynae work to top up with available capacity.
Just a final one from me. You've put through price increases. Did you get any resistance from customers?
I think our doctors are the best gauge for whether we can pull prices up. Our doctors are very supportive. Our decisions on price increases are very much based on inflation. Patients are converting as they normally do once they're aware of what the true price is for them. Our new patient registrations at that time is probably the first time they're fully aware of the price for them. New patient registrations are converting like they always have. The answer is no resistance.
Okay. Terrific. Thanks for that.
Thank you. Your next question comes from Benjamin Yuen from ORBS. Please go ahead.
Oh, good day, guys. You mentioned the margin expansion before. I was just wondering what you would consider your biggest drivers there and how we should think about the phasing of that.
Hey, Tom. The patient management system is going to be the primary driver. There is a lot of other things happening in the business. If you're asking what is the one that's really going to transform how we do things in our cost base, it's going to be the patient management system. Just the evolution of how we practice in our business needs to come up and be a little bit more contemporary, whether that is engaging with our patients and how we do that, how we interact with each other in the business, how we manage cycles through technology in the business, whether that's in lab or nursing. It's all of those elements that are super important with how we just do things in our business. We think technology is a big player there because we think we're a little bit behind the eight ball in that sense.
We do have a long list, Tom. Happy when we see you face to face, we can explore that in more detail.
Right. Makes sense. If we can talk about pricing, should we be expecting similar quantum and timing as to last year?
I don't—I mean, fairly to call, but I don't think it'll be 4% or 5%, to be honest. I think inflation, as quoted publicly, is around 2% to 3%. That's probably the best proxy for it. The timing will be in line with 1st July or new financial year, which also coincides with the timing of the Medicare rebate indexation.
Brilliant. Understood. Just the last one from me. In regards to your clinical infrastructure utilisation, how has the specialist recruitment been going? How much more do you have to go? If you could explain the calculation behind the 20% 10-year ROI hurdle?
Yeah. The question on doctors, it's not always just relative to doctor numbers, although they are important. It's about their priority in doing fertility treatments and fertility services and consulting. Our doctors tend to mix between obstetrics and gynae as well. In saying that, yes, absolutely. There are some really good capacity opportunities across our whole network as far as inviting doctors into our network and having a fixed cost base that is ready to build or do further treatments and deliver or create more babies. That is certainly something we are prioritizing.
We do not have an absolute number, but we search the market, scan the market. We have some really long relationships with doctors outside of our group as well that we continue to pursue. We will be sort of unrelenting in recruitment of doctors. I think the value proposition that we have for doctors is quite unique and special. We will make sure that continues to happen.
Brilliant. Just the last bit of that question, the 20% 10-year ROI hurdle, could you? Yeah. Yeah. Sorry.
I'll take that one. The 20% return on investment hurdle, that is a 10-year metric that we use for major investments in our organization. That is over the 10-year period. We're early in the infancy of the clinical infrastructure and generating that sort of 20% return on investment. Obviously, it's a lot stronger in the outlying years as you continually build and evolve. Certainly, we're pleased that the investments that we're making with what we know today are trending in the right direction.
Right. That's it from me, guys. Thank you.
Thank you.
Thank you. Your next follow-up question comes from David Stanton from Jefferies. Please go ahead.
Thanks, team. Just want to add two more if that's okay. I still don't quite understand why, compared to other states, Victoria is down industry-wide. I know you called out competition within that. I would have thought that would have driven more volume. Why are we seeing 20% plus on Medicare data volume declines in Victoria?
I think there's a level of resilience in our industry, absolutely, and the essential service that we provide. I think Victoria is no secret that it's been the most affected economic state. If you lived here during COVID and witnessed what we witnessed and the financial turmoil that followed COVID, it has been affected. Elective egg freezing, for example, is down more than in any other state, which is probably the most discretionary service that we have. I think it is the most impacted, albeit less impacted elsewhere, state in regards to the affordability element, particularly when it comes to elective egg freezing, David.
Understood. To that end, then, second question, you've talked to that slow demand for elective egg freezing. When we've spoken in the past, it's been about circa 10-15% of volume in Australia. Is that still correct? Is that the number we should be thinking about?
Yeah. That's right, David. When you dissect that, it's a question of what is truly elective versus medical in nature. That's a hard thing to gauge. We think around 40% of that 10-15% is true elective patients. If you do the math, we think around 5% of the industry is true elective in nature.
Understood. Thanks. Very clear.
Thank you. There are no further questions at this time. I'll now hand back the conference to Mr. Knaap for closing remarks.
Thanks. Look, thank you everyone for your time and interest in the Monash IVF Group. We look forward to meeting many of you and having a more detailed chat over the oncoming week. Thanks very much.